Adam is our Chief Business Officer. He joined Avilar in June 2022 after serving as Chief Business Officer of Flexion Therapeutics, where he was instrumental in the sale of the company to Pacira BioSciences for up to $1B in enterprise value. While at Flexion, Adam was a member of the executive committee and drove construction of a pipeline of novel drug candidates through asset acquisitions, executed a China development and commercialization deal for ZILRETTA®, and orchestrated the R&D efforts of Flexion’s Innovation Lab. Before joining Flexion, he was VP Business Development at Synta Pharmaceuticals and led the strategic transaction process culminating in a merger with Madrigal Pharmaceuticals. Prior to Synta, Adam held business development leadership positions at AMAG Pharmaceuticals, Inotek Pharmaceuticals, EPIX Pharmaceuticals, and Predix Pharmaceuticals, and also performed transaction/strategic advisory work at Locust Walk for biotech and pharmaceutical companies. He holds a BS in Engineering from the University of California, San Diego and a PhD in Biomedical Engineering from Duke University.
